An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according ...

Drugs giant GSK ‘well positioned’ to absorb potential US tariffs - It came as the FTSE 100 giant revealed a rise in sales as ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The company’s shares closed yesterday ...

Arizona sued drug manufacturer GlaxoSmithKline over what it calls deceptive practices involving the inhaled corticosteroid Flovent that endangered asthma patients. The lawsuit filed Thursday in ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

At GlaxoSmithKline, we never lose sight of the fact that patients are at the core of what we do and that millions of lives are impacted by cancer. The patient’s voice is at the heart of our ...

Jeanne Whalen writes about the U.S. economy from the Chicago bureau. She previously covered healthcare, general news and ...

In a report released today, Benjamin Jackson CFA from Jefferies maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. Protect Your ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

Chris Matthews leads The Wall Street Journal's U.S. energy coverage from the Journal's bureau in Houston.

In a report released today, Jo Walton from UBS maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of ...